Today: 9 June 2026
Lumentum stock price drops as rally cools — here’s what traders watch next
10 February 2026
1 min read

Lumentum stock price drops as rally cools — here’s what traders watch next

New York, Feb 10, 2026, 11:02 ET — Regular session

  • Lumentum shares dropped in morning trading, following a solid finish just the day before.
  • That rally has turned the stock into a bellwether for AI trends and cloud data-center outlays.
  • Next up, investors are watching for the upcoming slate of management appearances.

Lumentum Holdings Inc slipped 2.4% to $563.33 Tuesday, dropping from Monday’s $577.15 close. Shares traded as low as $531 and reached $579, despite both the S&P 500 and Nasdaq-tracking ETFs ticking up.

This drop is notable—Lumentum’s stock has become a high-beta bet tied closely to AI and cloud data center spend. The shares ran up fast, so when traders spot even a hint of overcrowding, they waste no time pulling back exposure.

Lumentum turned in fiscal Q2 revenue of $665.5 million last week, with adjusted earnings landing at $1.67 per share. Looking out to the third quarter, it’s projecting revenue between $780 million and $830 million, and expects adjusted operating margins to come in at 30% to 31%. CEO Michael Hurlston described the company as “only at the starting line” in optical circuit switches and co-packaged optics, noting a backlog for OCS “well beyond $400 million” and calling Lumentum “mission-critical to the world’s AI leaders.” (OCS are used to reroute light within data centers; co-packaged optics bring optical engines right up to switching chips—cutting power use and boosting speed.) Lumentum Investor Relations

Lumentum shares reached $599.50 at one point Monday, with roughly 5.9 million shares changing hands, Yahoo Finance data shows.

Action was uneven across optics stocks. Coherent slid 4.2%. Applied Optoelectronics added 2.5%. iShares Semiconductor ETF barely budged.

Investors have zeroed in on cadence—just how rapidly backlog converts to shipments, and if rising volumes still push margins higher rather than straining supply chains or nudging costs up again. Guidance is the reference point here, though tone on calls and in meetings also carries weight.

Still, there’s an obvious catch here. If hyperscalers pull back on orders or delay deliveries—and with expectations already high—any hint of pricing pressure in optical components could send shares tumbling faster than the broader market.

Next on the docket, Lumentum’s management plans to appear at the Susquehanna 15th Annual Technology Conference on Feb. 26, then at the Morgan Stanley Technology, Media & Telecom Conference on March 2. The company will also webcast one of the presentations.

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
BAT share price slips again as buyback filing lands and Capital Group trims stake ahead of results
Previous Story

BAT share price slips again as buyback filing lands and Capital Group trims stake ahead of results

Legal & General share price slips as AI disruption worries keep UK insurers on edge
Next Story

Legal & General share price slips as AI disruption worries keep UK insurers on edge

Go toTop